The efficacy of L- glutamine in sickle cell and sickell thalassemia
Phase 2
- Conditions
- sickle cell and sickell thalassemia.Sickle-cell disorders
- Registration Number
- IRCT20180603039959N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
patients with sickle cell and sickell thalassemia
Exclusion Criteria
Kidney impairment
Renal impaiment
HB <5 gr
Need to emergency transfusion
Pregnancy
Admition more than 10 times
Sensivity to glutamin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect to crisis event. Timepoint: at the end of fourth and eighth week. Method of measurement: pain-admition times-crisis.
- Secondary Outcome Measures
Name Time Method Crisis event. Timepoint: at the end of fourth and eight weeks. Method of measurement: Face Pain Scale.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie L-glutamine's efficacy in reducing vaso-occlusive crises in sickle cell disease and sickle thalassemia?
How does L-glutamine compare to hydroxyurea in managing pain crises for patients with sickle cell and sickle thalassemia in phase II trials?
Which biomarkers correlate with L-glutamine response in IRCT20180603039959N1 sickle cell disease patients?
What adverse events are associated with L-glutamine therapy in phase II trials for sickle cell and sickle thalassemia, and how are they managed?
Are there synergistic effects of combining L-glutamine with hydroxyurea or crizanlizumab in sickle cell disease treatment strategies?